About Paul Kleutghen

Articles by Paul Kleutghen

Allo-CAR-T: A Glimmer of Hope for Relapsed Plasma Cell Leukemia
Jul 31, 2026
Allo CAR-T: A Glimmer of Hope for Relapsed Plasma Cell Leukemia Patients
Dec 19, 2025
Insights From Treatment Patterns and Outcomes in Plasma Cell Leukemia (PCL)
Oct 06, 2025
Is It Possible To Be Resistant to Lenalidomide (Revlimid)?
May 19, 2025
CAR-T therapy and secondary hematological malignancies
May 12, 2025
Stem Cell Mobilization Options for Myeloma Patients: What’s Available and What’s Coming
Apr 28, 2025
Which CAR-T is the Best for You? Comparing Cilta-cel and Ide-cel
Apr 11, 2025
If MRD-Negative, is Stem Cell Transplant Still Needed for MCL?
Mar 19, 2025
Is It Time to Reduce Dex Dosages for Myeloma Patients?
Feb 11, 2025
New Biomaterial Shows Promise for Bone Healing in Myeloma Patients
Feb 03, 2025
Promising Results from Arlo-cel CAR T in Myeloma
Jan 09, 2025
BRCA Gene Testing in Multiple Myeloma: New Research Reveals Treatment Insights
Nov 28, 2024
A Better Understanding of Multiple Myeloma Biology
Oct 25, 2024
AML: Donor Age, Not Just a Number
Oct 24, 2024
Taking a Break from Lenalidomide Maintenance
Oct 18, 2024
Emerging Myeloma Treatments and Their Targets: Beyond BCMA
Sep 13, 2024
The Profound Impact of Socioeconomic Status in the Body
Sep 05, 2024
Recursos Útiles Para Pacientes con Mieloma Múltiple Que Están Considerando un Trasplante de Células Madre
Jul 08, 2024
What Are the NCCN Guidelines for Multiple Myeloma?
Jul 03, 2024
Un Nuevo Triplete Potencial Para el Tratamiento del Mieloma
Jun 04, 2024
CHIP and Multiple Myeloma: Impact on Stem Cell Transplant & Survival Rates
May 08, 2024
ORIC-533 : A New Small Molecule to Treat Multiple Myeloma
Apr 26, 2024
Tratamiento del Mieloma Múltiple Mediante la Explosión de Células Cancerosas
Jan 29, 2024
Risk of Infections Using Bispecific Antibodies in Multiple Myeloma
Jan 23, 2024